Sanofi creates a chain reaction among pharma companies.
Sanofi bought the stocks in 2004, and it owns approximately 23.2 million shares, which means 20.6% of Regeneron. The latter itself wants to repurchase its shares worth $5 billion. The overall value is $13 billion. The decision came shortly after Regeneron stocks reached an increase of 57% in the past six months.
Goldman Sachs and Bank of America will be the underwriters of the transaction, which will comprise of $3.5 billion in cash and $1.5 billion from Goldman itself.
If Sanofi manages to sell its stake in the company, it will be the most significant public offering in the health-care industry ever made. The money Sanofi will get from the transaction will go to "further our ability to execute on our strategy to drive innovation and growth" as the company wants to expand its research in oncology.
According to the companies, their partnership won’t stop as they have drugs in development.
The move made by Sanofi backs-up the rumor that it might repurchase a 9.4% stake in L’Oreal SA. By extension, it means that L’Oreal could buy back the 23% stake that Nestle owns from it.
Regeneron stock price lost 5% in pre-market trading. Sanofi dropped by 1%.
We know that the world is now in a precarious situation, and everybody rallies to find a cure against the novel virus. That's why we decided to give investors the possibility to trade on some of the most important pharmaceutical companies in the world that showed promising results in their search for a viable treatment. Using Capex.com, you can trade the Corona Blend made up of Johnson & Johnson, Pfizer, Gilead, Sanofi, Regeneron, Moderna, and Vir Biotechnology.
Sources: reuters.com, yahoo.com, seekingalpha.com
لا يجب على المستخدمين/القراء الاعتماد على المعلومات المقدمة هنا وحدها ويجب على المتلقي إجراء تحليلاته/أبحاثه الخاصة عن طريق قراءة البحث الأساسي الفعلي.تتسم المعلومات الواردة هنا بالعمومية ولا تأخذ في الاعتبار الظروف الشخصية لكل فرد، أو خبراته الاستثمارية أو وضعه المالي الحالي.
وبناء عليه، لن تتحمل Key Way Investments Ltd الأداء السابق للأصل المالي وتوقعات الأسواق ليست مؤشرات موثوقة للنتائج المستقبلية. لا يعتبر الأداء السابق مؤشراً موثوقاً على النتائج المستقبلية.